Clinical Trials on PD-L1 Gene Mutation

PD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation Tumor

Korea, Republic of

HIV Infections | HIV-1-infection | PD-L1 Gene Mutation

China

Lung Cancer | Non-small Cell Lung Cancer | PD-L1 Gene Mutation | KRAS Activating Mutation

United States

Metastatic Breast Cancer | Triple Negative Breast Cancer | PD-L1 Gene Mutation

Italy

Chemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 Inhibitor

China

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditions

United States

Healthy | GEN1 Gene Mutation

China

Non Small Cell Lung Cancer | Gene Mutation-Related Cancer | PD-L1 | PET/CT

France

Metastatic Breast Cancer | Triple Negative Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | PD-L1 Gene Mutation

United States

Recurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant Tumors

China

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | Sitravatinib

United States

Advanced PD-L1 Positive Malignancies

United States

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Italy, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditions

United States, Canada

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene Mutation

United States

BRCA1 Gene Mutation | BRCA2 Gene Mutation

Israel

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6... and other conditions

United States

BRCA1 Mutation | BRCA2 Mutation | APC Gene Mutation | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | PTEN Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | POLD1 Gene... and other conditions

United States

Metastatic Solid Tumor | SF3B1 Gene Mutation | Spliceosome Mutation | U2AF1 Gene Mutation | SRSF2 Gene Mutation

United States

Cancer | Cancer Gene Mutation | PAN Gene Mutation

United States

Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression

Netherlands

BRCA1 Gene Mutation | BRCA2 Gene Mutation

United States

Advanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene Alteration

United States

BRCA1 Gene Mutation | BRCA2 Gene Mutation

United States

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | KRAS Gene Mutation | Metastatic Malignant Solid Neoplasm | EGFR Gene Mutation | ERBB2 Gene Amplification | ERBB2 Gene Mutation | EGFR Gene Amplification | ERBB3 Gene Mutation | ERBB4 Gene Mutation

United States

Metastatic Solid Tumor | BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation

United States

Metastatic Gastric Cancer | FGFR2 Amplification | PD-L1 Gene Amplification

United States

Ovarian Cancer | BRCA1 Gene Mutation | BRCA2 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation

Netherlands, United States, Belgium, Norway, Poland, Italy, Australia, Mexico, Brazil, Sweden, Uruguay

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

France

Lung Cancer | ALK Gene Mutation | MET Gene Mutation | KRAS Mutation-Related Tumors | RET Gene Mutation | EGFR Gene Mutation | EGFR | ROS1 Gene Mutation | BRAF

United States

Metastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)

United States

Non Small Cell Lung Cancer | PD-L1 Gene Mutation | Advanced Lung Non-Small Cell Carcinoma

PD-L1-selected Solid Tumors

Korea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia

Chemotherapy | Immunotherapy | PD-L1

China

Cancer | Insulin Resistance | MTOR Gene Mutation | PI3K Gene Mutation | AKT Gene Mutation

United States

EGFR Gene Mutation

China

Glioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene Mutation

Australia

Hereditary Breast and Ovarian Cancer Syndrome | Premenopausal | Deleterious BARD1 Gene Mutation | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Deleterious BRIP1 Gene Mutation | Deleterious EPCAM Gene Mutation | Deleterious MLH1 Gene Mutation | Deleterious MSH2 Gene Mutation | Deleterious... and other conditions

United States

Cancer | Cancer Metastatic | BRAF V600E | MEK1 Gene Mutation | MEK2 Gene Mutation | ERK Mutation | RAF1 Gene Mutation

United States

BRCA1 Gene Mutation | BRCA2 Gene Mutation

Israel

Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer

Italy

TRPV4 Gene Mutation

United States

Cancer Gene Mutation

Italy

EGFR Gene Mutation

Bohring-Opitz Syndrome | ASXL1 Gene Mutation | Shashi-Pena Syndrome | ASXL2 Gene Mutation | Bainbridge-Ropers Syndrome | ASXL3 Gene Mutation

United States

Ductal Carcinoma in Situ | RAD51C Gene Mutation | RAD51D Gene Mutation | PALB2 Gene Mutation | Lobular Carcinoma in Situ | ATM Gene Mutation | CDH1 Gene Mutation | CHEK2 Gene Mutation | BRCA Mutation

Italy

Tumors | POLD1 Gene Mutation | POLE Exonuclease Domain Mutation

France

Cancer | Malignancies Multiple | Malignant Solid Tumor | Cancer, Therapy-Related | Molecular Sequence Variation | Genetic Alteration | Gene Fusion | Receptor Tyrosine Kinase Gene Mutation | RTK Family Gene Mutation | Ras (Kras or Nras) Gene Mutation

Canada

Refractory Lymphoma | DLBCL | MYD88 Gene Mutation | Relapse | CD79A Gene Mutation | CD79B Gene Mutation

Colorectal Cancer | APC Gene Mutation | TP53 Gene Mutation | PIK3CA Gene Mutation | KRAS Mutation-Related Tumors | MLH1 Gene Mutation

Indonesia